FREEPORT-MCMORAN INC (FCX)       40.91  +0.71 (+1.77%)

40.91  +0.71 (+1.77%)

US35671D8570 - Common Stock - After market: 40.9999 +0.09 (+0.22%)


Fundamental Rating

4

Overall FCX gets a fundamental rating of 4 out of 10. We evaluated FCX against 968 industry peers in the Metals & Mining industry. Both the profitability and the financial health of FCX get a neutral evaluation. Nothing too spectacular is happening here. FCX is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

4

FCX's Return On Equity of 22.22% is amongst the best of the industry. FCX does better than the industry average Return On Equity of 12.52%.
FCX's Return On Assets of 6.77% is in line with the rest of the industry. The industry average Return On Assets is 7.48%.

FCX's Profit Margin of 15.18% is in line with the rest of the industry. The industry average Profit Margin is 14.60%.
FCX has a Piotroski-F score of 5.00. This indicates an average health and profitability for FCX.
VS Industry

ROA (6.77%) VS Industry: 46% outperformed.

0.09
231.29

ROE (22.22%) VS Industry: 74% outperformed.

0.10
178.28

Profit Margin (15.18%) VS Industry: 51% outperformed.

0.68
1,966.43

Valuation

Valuation Rating

3

The Price/Earnings Ratio is 16.84, which indicates a correct valuation of FCX.
FCX's Price/Earning Ratio is in line with the industry average which is at 13.31.
With a Forward Price/Earnings Ratio of 22.01, FCX is valued rather expensively.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.

With a price book ratio of 3.76, FCX is valued correctly.
Compared to an average industry Enterprise Value to EBITDA ratio of 6.33, FCX is valued in line with its industry peers.
When comparing the price book ratio of FCX to the average industry price book ratio of 1.67, FCX is valued more expensive than its industry peers.
VS Industry

Price/Earnings (16.84) VS Industry: 42% outperformed.

1,128.00
0.15

Price/Book (3.76) VS Industry: 24% outperformed.

5,127.00
0.03

Enterprise Value/ EBITDA (6.63) VS Industry: 46% outperformed.

374.61
0.23

Growth

Growth Rating

3

The Earnings Per Share has been growing by 15.74% on average over the past 5 years. This is quite good.
Based on estimates for the next 5 years, FCX will show a small growth in Earnings Per Share. The EPS will grow by 5.27% on average per year.
The Revenue has decreased by -0.28% in the past year.
The Revenue has been growing slightly by 6.79% on average over the past 5 years.

Based on estimates for the next 5 years, FCX will show a small growth in Revenue. The Revenue will grow by 5.73% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.
FCX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.36%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS15.74% 395.29% -22.36% -23.51% -1.22% 1.85% 5.27%
Revenue6.79% 16.51% -0.28% 1% 3.93% 2.66% 5.73%

Health

Health Rating

5

FCX has a Current Ratio of 2.46. This indicates that FCX is financially healthy and has no problem in meeting its short term obligations.
FCX has a Current Ratio comparable to the industry average, which is at 2.52.
A Quick Ratio of 1.64 indicates that FCX should not have too much problems paying its short term obligations.
FCX has a Quick Ratio comparable to the industry average, which is at 2.14.

FCX has an Altman-Z score of 1.98. This is not the best score and indicates that FCX is in the grey zone with still only limited risk for bankruptcy at the moment.
FCX has a Altman-Z score comparable to the industry average, which is at 2.54.
FCX has a Piotroski-F score of 5.00. This indicates an average health and profitability for FCX.
Compared to an average industry Debt to Equity Ratio of 0.00, FCX is requires more financing than its industry peers. 96% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (0.62) VS Industry: 4% outperformed.

4.14
0.00

Quick Ratio (1.64) VS Industry: 42% outperformed.

0.00
178.59

Current Ratio (2.46) VS Industry: 48% outperformed.

0.00
178.59

Altman-Z (1.98) VS Industry: 45% outperformed.

-22,403.49
2,514.55

Dividend

Dividend Rating

5

The dividend of FCX is nicely growing with an annual growth rate of 44.22%!
25.05% of the earnings are spent on dividend by FCX. This is a low number and sustainable payout ratio.
FCX has been paying a dividend for at least 10 years, so it has a reliable track record.
FCX has a Yearly Dividend Yield of 1.66%.

FCX's Dividend Yield is comparable with the industry average which is at 2.10.
FCX's Dividend Yield is slightly below the S&P500 average, which is at 2.60.
FCX's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
VS Industry

Dividend Yield (1.66%) VS Industry: 41% outperformed.

0.27
24.74

FREEPORT-MCMORAN INC40.91

NYSE:FCX (3/31/2023, 4:48:27 PM)+0.71 (+1.77%)

After market: 40.9999 +0.09 (+0.22%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)01-25 2023-01-25/bmo
Earnings (Next)04-19 2023-04-19/bmo
Inst Owners79.27%
Inst Owner Change3.32%
Ins Owners0.44%
Ins Owner Change17.66%
Market Cap58.53B
Analysts73.08
Price Target46.44 (13.52%)
Dividend
Industry RankSector Rank
Dividend Yield 1.66%
Dividend Growth(5Y)44.22%
DP25.05%
Div Incr Years2
Div Non Decr Years2
Ex-Date04-13 2023-04-13 (0.15)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.61%
Min EPS beat(2)5.38%
Max EPS beat(2)11.84%
EPS beat(4)3
Avg EPS beat(4)5.93%
Min EPS beat(4)-6.4%
Max EPS beat(4)12.91%
Revenue beat(2)2
Avg Revenue beat(2)2.95%
Min Revenue beat(2)1.48%
Max Revenue beat(2)4.43%
Revenue beat(4)3
Avg Revenue beat(4)-1.24%
Min Revenue beat(4)-12.57%
Max Revenue beat(4)4.43%
PT rev (1m)2.78%
PT rev (3m)17.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.16%
EPS NY rev (1m)6.78%
EPS NY rev (3m)6.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.26%
Revenue NY rev (1m)3.47%
Revenue NY rev (3m)3.47%
Valuation
Industry RankSector Rank
PE 16.84
Fwd PE 22.01
P/S 2.57
P/FCF 32.09
P/OCF 11.39
P/B 3.76
P/tB 3.87
EV/EBITDA 6.63
EPS(TTM)2.43
EY5.94%
EPS(NY)1.86
Fwd EY4.54%
FCF(TTM)1.27
FCFY3.12%
OCF(TTM)3.59
OCFY8.78%
SpS15.92
BVpS10.87
TBVpS10.58
PEG (NY)N/A
PEG (5Y)1.07
Profitability
Industry RankSector Rank
ROA 6.77%
ROE 22.22%
ROIC 10.71%
ROICexc 13.09%
ROICexgc 13.24%
OM 30.88%
PM 15.18%
GM 33.76%
ROICexgc(3y)11.46%
ROICexcg growth 3Y117.18%
ROICexcg growth 5Y8.31%
ROICexc(3y)11.33%
ROICexc growth 3Y117.24%
ROICexc growth 5Y8.3%
OM growth 3Y88.22%
OM growth 5Y7.11%
PM growth 3YN/A
PM growth 5Y6.57%
GM growth 3Y56.5%
GM growth 5Y5.02%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF 5.82
Debt/EBITDA 1.17
Cap/Depr 164.19%
Profit Quality 52.76%
Current Ratio 2.46
Quick Ratio 1.64
Altman-Z 1.98
F-Score5
WACC9.74%
ROIC/WACC1.36
Cap/Depr(3y)132.79%
Cap/Depr(5y)139.72%
Profit Quality(3y)120.05%
Profit Quality(5y)N/A
Growth
EPS 1Y-22.36%
EPS 3Y395.29%
EPS 5Y15.74%
EPS growth Q2Q-45.83%
EPS Next Y-23.51%
EPS Next 2Y-1.22%
EPS Next 3Y1.85%
EPS Next 5Y5.27%
Revenue growth 1Y-0.28%
Revenue growth 3Y16.51%
Revenue growth 5Y6.79%
Revenue growth Q2Q-6.59%
Revenue Next Year1%
Revenue Next 2Y3.93%
Revenue Next 3Y2.66%
Revenue Next 5Y5.73%
EBIT growth 1Y-15.1%
EBIT growth 3Y119.3%
EBIT growth 5Y14.38%
EBIT Next Year33.43%
EBIT Next 3Y18.3%
EBIT Next 5Y16.39%
FCF growth 1Y-67.43%
FCF growth 3YN/A
FCF growth 5Y-10.94%
OCF growth 1Y-33.39%
OCF growth 3Y51.36%
OCF growth 5Y1.95%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA